Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer
Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer
复制标题
DOI：
10.1097/mnm.0000000000000959
复制
发表时间：
2019-03-01
影响因子：
1.5
通讯作者：
Ciarmiello, Andrea
中科院分区：
文献类型：
--
作者：
Giovacchini, Giampiero;Giovannini, Elisabetta;Ciarmiello, Andrea
目的：探讨前列腺癌患者因生化检查失败行PET/CT检查时，F-18-FCH阳性PET/CT结果的预测因素。在这些因素中，前列腺特异性抗原（PSA）是与阳性F-18-FCH PET/CT预测最一致的单一因素。在这项研究中，我们希望证实这一发现，并扩大它在一个大系列的患者。患者和方法我们回顾性分析了2013年3月至2018年3月从意大利La Spezia的Sant'Andrea医院核医学部招募的192例前列腺癌患者，这些患者因根治性前列腺切除术后生化失败而接受了F-18-FCH PET/CT。结果中位触发PSA为2.57ng/ml。F-18-FCH PET/CT的总体阳性检出率为60.9%。PSA <1 ng/ml者阳性率为30.5%，1 ~ 5 ng/ml者阳性率为59.4%（38/64），> 5 ng/ml者阳性率为88.4%（P
Purpose Several factors have been identified that predict positive fluorine-18-fluoromethylcholine (F-18-FCH) PET/CT result in patients with prostate cancer undergoing PET/CT for biochemical failure. Among these factors, prostate-specific antigen (PSA) is the single factor most consistently associated with the prediction of positive F-18-FCH PET/CT. In this study, we wished to confirm this finding and expand it in a large series of patients. Patients and methods We retrospectively analyzed 192 patients with prostate cancer who were recruited from the Nuclear Medicine Department of the Sant'Andrea Hospital of La Spezia, Italy, from March 2013 to March 2018 and who underwent F-18-FCH PET/CT owing to biochemical failure after radical prostatectomy. Results Median trigger PSA was 2.57 ng/ml. The overall positive detection rate of F-18-FCH PET/CT was 60.9%. The percent of positive scans was 30.5% for PSA less than 1 ng/ml, 59.4% (38/64) for PSA between 1 and 5 ng/ml, and 88.4% for PSA greater than 5 ng/ml (P